Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

We describe a high-throughput colorimetric assay measuring β-galactosidase activity in three life cycle stages of Trypanosoma cruzi, the causative agent of Chagas disease. This assay can be used to identify trypanocidal compounds in an easy, fast, and reproducible manner.

Abstract

Trypanosoma cruzi is the causative agent of Chagas disease (ChD), an endemic disease of public health importance in Latin America that also affects many non-endemic countries due to the increase in migration. This disease affects nearly 8 million people, with new cases estimated at 50,000 per year. In the 1960s and 70s, two drugs for ChD treatment were introduced: nifurtimox and benznidazole (BZN). Both are effective in newborns and during the acute phase of the disease but not in the chronic phase, and their use is associated with important side effects. These facts underscore the urgent need to intensify the search for new drugs against T. cruzi.

T. cruzi is transmitted through hematophagous insect vectors of the Reduviidae and Hemiptera families. Once in the mammalian host, it multiplies intracellularly as the non-flagellated amastigote form and differentiates into the trypomastigote, the bloodstream non-replicative infective form. Inside the insect vector, trypomastigotes transform into the epimastigote stage and multiply through binary fission.

This paper describes an assay based on measuring the activity of the cytoplasmic β-galactosidase released into the culture due to parasites lysis by using the substrate, chlorophenol red β-D-galactopyranoside (CPRG). For this, the T. cruzi Dm28c strain was transfected with a β-galactosidase-overexpressing plasmid and used for in vitro pharmacological screening in epimastigote, trypomastigote, and amastigote stages. This paper also describes how to measure the enzymatic activity in cultured epimastigotes, infected Vero cells with amastigotes, and trypomastigotes released from the cultured cells using the reference drug, benznidazole, as an example. This colorimetric assay is easily performed and can be scaled to a high-throughput format and applied to other T. cruzi strains.

Introduction

Chagas disease (ChD), or American trypanosomiasis, is a parasitic disease caused by the flagellated protozoan, Trypanosoma cruzi (T. cruzi). ChD begins with an asymptomatic or oligosymptomatic acute phase that is usually undiagnosed, followed by a lifelong chronic phase. In the chronicity, ~30% of patients manifest-decades after the infection-a variety of debilitating conditions, including myocardiopathy, mega-digestive syndromes, or both, with a mortality rate ranging from 0.2% to 20%1,2,3. Asymptomatic chronic patients may have no clinical signs but remain....

Protocol

NOTE: An overview of the entire experimental design is depicted in Figure 1.

figure-protocol-193
Figure 1: Overview of the in vitro screening assay of Trypanosoma cruzi Dm28c/pLacZ line using CPRG as a substrate for the colorimetric reaction. The assay consists of seeding the parasites (1), incubati.......

Representative Results

Following the protocol described above, β-galactosidase-expressing Dm28c epimastigotes were incubated with 6 concentrations of BZN (2.5, 5, 10, 20, 40, 80 µM) (or compounds of interest) for 72 h. After this period, CPRG reagent was added along with detergent, which lyses the cells and releases β-galactosidase. CPRG is cleaved by the β-galactosidase to produce chlorophenol red, leading to a change in color from yellow to reddish (Figure 2A). Chlorophenol red was measured b.......

Discussion

This paper describes an assay based on determining the cytoplasmic β-galactosidase activity released due to membrane lysis of T. cruzi epimastigotes, trypomastigotes, or infected cells with amastigotes in the presence of the substrate CPRG. We used T. cruzi Dm28c/pLacZ parasites, a stable parasite strain obtained after transfection with a β-galactosidase-bearing plasmid constructed by Buckner and co-authors10. This assay has been used to search for antitrypanocidal comp.......

Acknowledgements

We thank Dr. Buckner for kindly providing the pLacZ plasmid. This work was supported by Agencia Nacional de Promoción Científica y Tecnológica, Ministerio de Ciencia e Innovación Productiva from Argentina (PICT2016-0439, PICT2019-0526, PICT2019-4212), and Research Council United Kingdom [MR/P027989/1]. Servier Medical Art was used to produce Figure 1 (https://smart.servier.com).

....

Materials

NameCompanyCatalog NumberComments
1 L beakerSchott Duran10005227
10 mL serological pipette sterileJet BiofilGSP211010
5 mL serological pipette sterileJet BiofilGSP010005
96-well platesCorning3599
BenznidazoleSigma Aldrich419656N-Benzyl-2-nitro-1H-imidazole-1-acetamide
Biosafty CabinetTelstarBio II A/P
Centrifuge tube 15 mL conical bottom sterileTarson546021
Centrifuge tube 50 mL conical bottom sterileTarson546041
CO2 IncubatorSanyoMCO-15A
CPRGRoche10 884308001Chlorophenol Red-β-D-galactopyranoside
DMEM, High GlucoseThermo Fisher Cientific12100046Powder
DMSOSintorganSIN-061Dimethylsulfoxid
Fetal Calf SerumInternegocios SAFCS FRA 500Sterile and heat-inactivated
G418 disulphate salt solutionRocheG418-ROstock concentration: 50 mg/mL
Glucose D(+)Cicarelli716214
Graduated cylinderNalgene3663-1000
HeminFrontier ScientificH651-9
KClCicarelli867212
Liver InfusionDifco226920
Microcentrifuge tube 1.5 mLTarson500010-N
Microplate SpectrophotometerBiotekSynergy HTX
Na2HPO4Cicarelli834214
NaClCicarelli750214
Neubauer chamberBoecoBOE 01
Nonidet P-40AntraceNIDP402-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol
PrismGraphpadStatistical Analysis software
Sodium BicarbonateCicarelli929211NaHCO3
Sorvall ST 16 CentrifugeThermo Fisher Cientific75004380
T-25 flasksCorning430639
TryptoseMerck1106760500
Vero cellsATCCCRL-1587

References

  1. Rassi, A., Rassi, A., Rassi, S. G. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 115 (9), 1101-1108 (2007).
  2. Pérez-Molina, J. A., Molina, I. Chagas disease.

Explore More Articles

Trypanosoma CruziIn Vitro Drug ScreeningHigh throughput Colorimetric AssayParasite Life Cycle StagesEpimastigotesTrypomastigotesVero CellsBeta galactosidaseChagas DiseaseDrug Discovery

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved